Status:

COMPLETED

Enalapril After Anthracycline Cardiotoxicity

Lead Sponsor:

National Heart, Lung, and Blood Institute (NHLBI)

Conditions:

Cardiovascular Diseases

Heart Diseases

Eligibility:

All Genders

1-17 years

Phase:

PHASE3

Brief Summary

To determine if the chronic administration of enalapril, an inhibitor of angiotensin converting enzyme (ACE), reduces progression of cardiac dysfunction in pediatric oncology patients who have receive...

Detailed Description

BACKGROUND: Pediatric oncology patients who have been treated with anthracycline therapy as a part of their chemotherapeutic regimen often subsequently develop left ventricular failure. The optimal m...

Eligibility Criteria

Boy and girl pediatric oncology patients, at least two years off treatment, with some cardiac dysfunction, but not congestive heart failure, after receiving anthracyclines. Patients were not on digoxin, diuretics, or vasodilators for heart failure.

Key Trial Info

Start Date :

April 1 1994

Trial Type :

INTERVENTIONAL

End Date :

February 1 2001

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT00000547

Start Date

April 1 1994

End Date

February 1 2001

Last Update

July 12 2016

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

Enalapril After Anthracycline Cardiotoxicity | DecenTrialz